Medvi telemedicine startup faces allegations of fake doctor profiles and weight loss stories
The telemedicine startup Medvi, offering online sales of weight loss drugs, is under suspicion for fabricating doctor profiles and user weight loss testimonials. The New York Times reported on Matthew Gallagher, the founder who launched the business with his brother in September 2024, investing $20,000.
Within just two months, using artificial intelligence tools like ChatGPT, Claude, Grok, Midjourney, and Runway, Matthew developed the website, advertising, chatbots, and analytics system. The company employs almost no full-time staff, relying instead on contractors and ready-made platforms. Gallagher himself manages marketing and automation.
According to the startup, revenue in 2025 reached $401 million, with a forecast of $1.8 billion for 2026. Net profit is estimated at $70-80 million, and the company has not attracted external investors. The team has grown to seven managers, and further scaling depends heavily on AI. Prominent entrepreneur Sam Altman has cited Medvi as an example of a “one-person company” valued at over $1 billion.
Critics have noted questionable data: in May 2025, Futurism described Medvi as a dubious startup that nevertheless received a professional award, raising additional concerns about data authenticity.
Medvi is a newcomer in the telemedicine field focusing on online sales of weight loss medications, leveraging advanced artificial intelligence technologies. The company emphasizes automation to reduce costs and boost profitability.
Overall, Medvi demonstrates rapid financial growth and innovative approaches but faces serious ethical issues that could affect its reputation and future development.
The outlook suggests that Medvi may either consolidate its position as a technological leader or lose investor and consumer trust amid ongoing doubts over its data credibility.
